Editorial Commentary: The challenge of preventing invasive pneumococcal disease in children with comorbid illnesses

Clinical Infectious Diseases

Volumn 58, Issue 4, 2014, Pages 526-527

  Pelton, Stephen I ^a  

^a BOSTON UNIVERSITY   (United States)

Author keywords

comorbid illness; nonvaccine serotypes; pneumococcal disease; pneumococcal polysaccharide vaccine

Indexed keywords

PNEUMOCOCCUS VACCINE; 23-VALENT PNEUMOCOCCAL CAPSULAR POLYSACCHARIDE VACCINE;

CHRONIC LUNG DISEASE; COMORBIDITY; HERD IMMUNITY; NOTE; PEDIATRICS; PNEUMOCOCCAL INFECTION; PNEUMONIA; PRIORITY JOURNAL; SEROTYPE; FEMALE; HUMAN; MALE; PNEUMOCOCCAL INFECTIONS;

FEMALE; HUMANS; MALE; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES;

EID: 84893313407     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cit792     Document Type: Note

References (7)

1. Ladhani SN, Andrews NJ, Waight P, Borrow R, Slack MPE, Miller E. Invasive pneumococcal disease, comorbidity, and polysaccharide vaccine use in children aged 5-15 years in England and Wales. Clin Infect Dis 2014; 58:517-25.
2. Pelton SI, Weycker D, Farkouh RA, Strutton DR, Shea KM, Edelsberg J. Increased risk of invasive pneumococcal disease and pneumonia in children with chronic medical conditions. In: 31st Meeting of the European Society for Paediatric Infectious Diseases, Milan Italy, 28 May-1 June 2013.
3. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among children aged 6-18 years with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep 2013; 62:521-4.
4. Whitney CG, Pilishvili T, Farley MM, Schaffner W, Craig AS, Lynfield R, et al. Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a case-control study. Lancet 2006; 368: 1495-1502.
5. Laferriere C. The immunogenicity of pneumococcal polysaccharides in infants and children: a meta-regression. Vaccine 2011; 29: 6838-47.
6. Balmer P, Borrow R, Arkwright PD. The 23-valent pneumococcal polysaccharide vaccine does not provide additional serotype antibody protection in children who have been primed with two doses of heptavalent pneumococcal conjugate vaccine. Vaccine 2007; 25:6321-5.
7. Vila-Corcoles A, Ochoa-Gondar O, Rodriguez-Blanco T, Gutierrez-Perez A, Vila-Rovira A. Clinical effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumonia in patients with chronic pulmonary diseases: a matched case-control study. Hum Vaccin Immunother 2012; 8:639-44.